checkAd

     104  0 Kommentare Cara Therapeutics to Host Virtual R&D Day on March 11, 2022

    Presentation to highlight oral difelikefalin Phase 3 pruritus programs

    STAMFORD, Conn., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a virtual research and development (R&D) event on Friday, March 11, 2022, from 1:00 to 2:00 p.m. ET. The presentation will focus on the initiation of oral difelikefalin Phase 3 programs for the treatment of pruritus in patients with atopic dermatitis and non-dialysis dependent chronic kidney disease. An interactive Q&A session will follow the presentation.

    Presenters will include:

    • Christopher Posner, President & Chief Executive Officer and Director of Cara Therapeutics
    • Joana Goncalves, MD, Chief Medical Officer of Cara Therapeutics
    • Brian Kim, MD, MTR, Icahn School of Medicine at Mount Sinai, NY
    • Jonathan Silverberg, MD, PhD, MPH, George Washington University School of Medicine and Health Sciences

    A live audio webcast of the presentation and accompanying slides will be accessible under “Events & Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com. A replay of the webcast will be archived on the Company’s website following the presentation.

    About Cara Therapeutics

    Cara Therapeutics is an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s novel KORSUVA (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and plans to initiate Phase 3 programs in the first quarter of 2022 for the treatment of pruritus in patients with atopic dermatitis and non-dialysis-dependent chronic kidney disease. Phase 2 trials of oral difelikefalin are ongoing in primary biliary cholangitis and notalgia paresthetica patients with moderate-to-severe pruritus. For more information, visit www.CaraTherapeutics.com and follow the company on Twitter, LinkedIn and Instagram.

    MEDIA CONTACT:
    Annie Spinetta
    6 Degrees
    973-768-2170
    aspinetta@6degreespr.com

    INVESTOR CONTACT:
    Iris Francesconi, Ph.D.
    Cara Therapeutics
    203-406-3700
    investor@caratherapeutics.com





    globenewswire
    0 Follower
    Autor folgen
    Verfasst von globenewswire
    Cara Therapeutics to Host Virtual R&D Day on March 11, 2022 Presentation to highlight oral difelikefalin Phase 3 pruritus programsSTAMFORD, Conn., Feb. 18, 2022 (GLOBE NEWSWIRE) - Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to …